Vygenerované: 25.06.2026 19:22:21
Súhrn: One of the indications is for use as a single agent for patients who are not candidates for PD-1 or PD-L1 inhibitor-based therapy A rival TROP2-directed ADC — datopotamab deruxtecan— is also indicated in the first-line setting for unresectable or metastatic TNBC but only in patients who are not candidates for anti-PD-L1 therapy Approval for the monotherapy indication was based on the ASCENT-03 trial in 558 anti-PD-L1 ineligible patients.
Doplnenie: The approvals make the TROP2-directed antibody-drug conjugate (ADC) the only ADC to carry a first-line metastatic TNBC indication regardless of anti-PD-L1 eligibility.